Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chemical Abstracts Service has announced a landmark five-year agreement for SciFinder, the choice for chemistry research, with AstraZeneca.
Subscribe to our email newsletter
The long-term agreement guarantees AstraZeneca researchers access to the most accurate, comprehensive and current research, available only in SciFinder.
AstraZeneca Screening Sciences and Sample Management vice president Steve Rees noted SciFinder has played an important role in our research into the development of innovative, life-saving medicines.
"This partnership will support our worldwide R&D teams with the tools and knowledge they need to advance discoveries that will ultimately make a difference in the lives of patients across the globe," Rees added.
An early adopter of Enterprise-Wide Pricing, AstraZeneca has relied on SciFinder to meet the needs of its researchers for nearly a decade, and this five-year agreement is a first for SciFinder within the pharmaceutical industry. It signifies the confidence customers have in CAS as a high-quality information partner providing reliable access to the most up-to-date research in the chemical industry and beyond.
CAS marketing vice president of Chris McCue noted the trust that AstraZeneca shows in SciFinder by entering into this agreement exemplifies that our content spans a multitude of scientific disciplines while maintaining the highest levels of excellence.
"Such a long-term contract sends a clear message that SciFinder is a product the biopharmaceutical industry considers essential for its research needs," McCue added.